Compare RMCO & TELA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RMCO | TELA |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.3M | 41.3M |
| IPO Year | N/A | 2019 |
| Metric | RMCO | TELA |
|---|---|---|
| Price | $2.62 | $0.88 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $2.00 |
| AVG Volume (30 Days) | 36.9K | ★ 127.3K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | N/A | ★ 37.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $80,275,000.00 |
| Revenue This Year | $209.10 | $10.23 |
| Revenue Next Year | $133.33 | $14.26 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 15.84 |
| 52 Week Low | $1.05 | $0.50 |
| 52 Week High | $5.00 | $2.19 |
| Indicator | RMCO | TELA |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 52.24 |
| Support Level | $1.94 | $0.67 |
| Resistance Level | $3.14 | $1.24 |
| Average True Range (ATR) | 0.35 | 0.11 |
| MACD | 0.05 | -0.01 |
| Stochastic Oscillator | 75.86 | 52.26 |
Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
TELA Bio Inc a commercial-stage medical technology company focused on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.